Medical Writing Careers in medical writing Clinical trial disclosure landscape and awareness in Japan

Volume 28, Issue 1 - Careers in medical writing

Clinical trial disclosure landscape and awareness in Japan

Abstract

While disclosure of individual clinical study reports (CSRs) is becoming common globally, this is not yet the case in Japan, where the national health authority does not require CSRs to be made publicly available. As CSRs of Japanese studies might be used for marketing applications in other countries and regions, Japanese pharmaceutical companies that would like to expand their market internationally need to prepare CSRs that can be used for global applications and disclosure. In this article, we introduce the current situation in Japan regarding disclosure of clinical study data.

Download the full article

References

  1. The Government of Japan. Act on access to information held by administrative organs. Act No. 42. 1999 May 14 [cited 2019 Jan 18]. Available from: http://elaws.e-gov. go.jp/search/elawsSearch/elaws_search/ lsg0500/detail?lawId=411AC0000000042. Japanese
  2. Procedural guidance for administrative processing related to access to information held by the Pharmaceutical and Food Safety Bureau. PFSB Notification No. 0330022 from the Director General of the Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. 2007 Mar 30 [cited 2019 Jan 18]. Available from: https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0020.html
  3. Procedures for public release of information on review of applications for new drug. PMDA Notification No. 0325004 from the Chief Executive of the Pharmaceuticals and Medical Devices Agency. 2013 March 25 [cited 2019 Jan 18]. Available from: https://www.pmda.go.jp/files/000204879. pdf. Japanese.
  4. Viergever RF, Li K. Trends in global clinical trial registration: an analysis of numbers of registered clinical trials in different parts of the world from 2004 to 2013. BMJ Open. 2015;5(9):e008932.
  5. Ministry of Health, Labour and Welfare. Ethical guidelines for clinical research in Japan. Notification No. 0731001 from the Director of the Health Bureau, Ministry of Health, Labour and Welfare. Revised 2008 Jul 31 [cited 2019 Jan 18]. Available from: https://www.mhlw.go.jp/general/seido/ kousei/i-kenkyu/rinsyo/dl/shishin.pdf. Japanese.
  6. Ministry of Health, Labour and Welfare, Ministry of Education, Culture, Sports, Science and Technology. Ethical guidelines for medical and health research involving human subject. Notification No. 0228-1 from Director of Health Bureau, Ministry of Health, Labour and Welfare, Notification No. 28-406 from the Director General of the Research Promotion Bureau, Ministry of Education, Culture, Sports, Science and Technology. Revised 2017 Feb 28 [cited 2019 Jan 18]. Available from: https://www.mhlw.go.jp/file/06- Seisakujouhou-10600000- Daijinkanboukouseikagakuka/0000153339 .pdf. Japanese.
  7. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ. 2016;352:i637.
  8. Tang W, Fukuzawa M, Ishikawa H, Tsutani K, Kiuchi T. Review of the registration of clinical trials in UMIN-CTR from 2 June 2005 to 1 June 2010 - focus on Japan domestic, academic clinical trials. Trials. 2013;14:333.
  9. Ochi N, Kawahara T, Nagasaki Y, Nakagawa N, Yamagishi T, Umemura S, et al. Publication of lung cancer clinical trials in the Japanese Clinical Trial Registry. Jpn J Clin Oncol. 2018;48(11):995–1000.
  10. Ministry of Health, Labour and Welfare. Format for preparing the common technical document for submission of new drug applications to reduce total review time. Administrative notice from the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. 2011 Jan 17 [cited 2019 Jan 18]. Available from: https://www.pmda.go.jp/files/000209183. pdf. Japanese.
  11. Hamilton S, Bernstein AB, Blakey G, Fagan V, Farrow T, Jordan D, et al. Developing the Clarity and Openness in Reporting: E3-based (CORE) Reference user manual for creation of clinical study reports in the era of clinical trial transparency. Res Integr Peer Rev. 2016;1(1):4.
  12. Ebina H, Fagan V, Gertel A. Driving international awareness and use of regulatory writing guidelines: case studies of the Clarity and Openness in Reporting (CORE) Reference guidelines. Drug Information Association (DIA) 2017 Global Annual Meeting, Chicago, July 18–22, 2017 (presentation).

Search

Articles

Careers in medical writing
President’s Message
EMWA News
How to get your first job as a medical writer
Educating the medical writer: A 5-year update
Cheeky medical writers: Transitioning from academia to medical writing
Making the leap: My move from academia to medical writing
From bench to pen: Life as a new medical writer
The grass is always greener on the other side
Pharmaceutical writer or CRO writer – choosing the right path
Career shift: Employment to freelancing
Medical writing and medical translation – two crossing paths
Career opportunities in medical device writing: Employee and freelance perspectives
Career shifts – surviving a change in geography
Grant writing and editing
1000 words in 1 picture
Medical writing at the management level
Thriving (and not just surviving) in a VUCA healthcare industry
Elevate your medical writing team to success
Clinical trial disclosure landscape and awareness in Japan
News from the EMA
Regulatory Matters
Gained in Translation
In the Bookstores
Medical Devices
Journal Watch
Veterinary Medical Writing
Good Writing Practice
Medical Communication
Regulatory Public Disclosure
Out on Our Own
Vignettes - Life After Medical Writing

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Managing Editor

show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: